Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 27 04:00PM ET
2.96
Dollar change
+0.13
Percentage change
4.59
%
Index- P/E- EPS (ttm)-7.00 Insider Own14.86% Shs Outstand14.10M Perf Week35.78%
Market Cap41.74M Forward P/E- EPS next Y-5.63 Insider Trans0.62% Shs Float12.00M Perf Month24.89%
Income-28.44M PEG- EPS next Q-0.24 Inst Own60.77% Short Float0.10% Perf Quarter17.93%
Sales0.42M P/S99.37 EPS this Y-109.18% Inst Trans-23.16% Short Ratio0.10 Perf Half Y-17.75%
Book/sh6.29 P/B0.47 EPS next Y-9.85% ROA-40.27% Short Interest0.01M Perf Year10.45%
Cash/sh6.62 P/C0.45 EPS next 5Y- ROE-46.40% 52W Range1.67 - 8.73 Perf YTD27.04%
Dividend Est.- P/FCF- EPS past 5Y56.16% ROI-32.02% 52W High-66.09% Beta1.20
Dividend TTM- Quick Ratio12.73 Sales past 5Y877.51% Gross Margin- 52W Low77.25% ATR (14)0.24
Dividend Ex-Date- Current Ratio12.73 EPS Y/Y TTM39.57% Oper. Margin-6900.71% RSI (14)76.54 Volatility18.36% 10.07%
Employees10 Debt/Eq0.00 Sales Y/Y TTM-11.11% Profit Margin-6708.02% Recom1.00 Target Price5.58
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q94.02% Payout- Rel Volume2.38 Prev Close2.83
Sales Surprise-49.33% EPS Surprise64.00% Sales Q/Q1166.67% EarningsFeb 29 BMO Avg Volume120.38K Price2.96
SMA2032.04% SMA5040.26% SMA200-11.53% Trades Volume286,558 Change4.59%
Date Action Analyst Rating Change Price Target Change
Dec-06-21Resumed H.C. Wainwright Buy $7
Mar-19-24 08:00AM
Mar-13-24 09:55AM
Mar-08-24 12:00PM
Feb-29-24 08:00AM
Feb-27-24 08:00AM
08:00AM Loading…
Feb-21-24 08:00AM
Jan-10-24 08:00AM
Jan-03-24 08:00AM
Nov-13-23 07:45AM
Nov-07-23 08:00AM
Nov-01-23 04:15PM
Oct-30-23 07:20AM
07:05AM
07:00AM
Sep-06-23 08:00AM
08:00AM Loading…
Aug-14-23 08:00AM
May-18-23 08:00AM
May-11-23 04:01PM
May-01-23 08:00AM
Apr-19-23 08:00AM
Mar-30-23 07:45AM
Mar-22-23 08:00AM
Mar-09-23 04:01PM
Feb-28-23 04:00PM
Feb-22-23 08:00AM
Feb-15-23 08:00AM
Feb-10-23 08:00AM
Jan-09-23 04:01PM
Dec-12-22 08:00AM
Dec-07-22 08:00AM
08:00AM Loading…
Dec-02-22 08:00AM
Nov-18-22 08:00AM
Nov-17-22 08:00AM
Nov-10-22 04:01PM
Sep-06-22 08:00AM
Aug-12-22 08:00AM
Aug-10-22 08:32AM
Jul-19-22 08:00AM
Jun-17-22 08:00AM
May-18-22 08:00AM
May-12-22 04:05PM
May-10-22 08:00AM
May-06-22 08:00AM
May-05-22 02:06PM
Apr-28-22 03:02PM
Apr-07-22 08:00AM
Mar-30-22 08:00AM
Mar-17-22 08:00AM
Mar-07-22 07:00AM
Mar-03-22 08:00AM
Jan-19-22 08:00AM
Jan-13-22 07:00AM
Jan-03-22 08:00AM
Dec-13-21 12:08PM
Nov-18-21 08:00AM
Nov-12-21 01:09PM
Nov-10-21 07:30AM
Nov-04-21 08:00AM
Oct-28-21 03:05PM
08:00AM
Oct-26-21 08:00AM
Oct-21-21 08:00AM
Oct-19-21 08:00AM
Oct-05-21 08:00AM
Sep-20-21 08:00AM
Sep-08-21 08:00AM
Aug-13-21 07:11AM
Aug-12-21 07:30AM
07:00AM
Aug-11-21 08:43AM
Aug-05-21 03:01PM
Aug-02-21 08:00AM
Jul-27-21 08:00AM
Jul-19-21 08:00AM
Jun-29-21 08:00AM
Jun-08-21 09:34AM
May-06-21 07:00AM
Apr-28-21 08:00AM
Apr-22-21 08:14AM
Mar-04-21 04:01PM
07:00AM
06:30AM
Mar-01-21 04:01PM
08:00AM
Feb-18-21 10:16AM
Feb-17-21 12:46AM
Feb-16-21 12:02PM
Feb-11-21 08:00AM
Feb-01-21 08:00AM
Jan-29-21 08:00AM
Jan-26-21 07:59AM
Jan-21-21 08:00AM
Jan-05-21 08:00AM
Dec-24-20 05:53AM
Dec-17-20 08:00AM
Dec-16-20 08:00AM
Dec-15-20 08:00AM
Dec-09-20 10:29PM
Dec-01-20 08:00AM
Nov-25-20 08:00AM
VYNE Therapeutics, Inc. engages in the manufacture of pharmaceutical products. It develops and commercializes solutions using its proprietary Molecule Stabilizing Technology. Its commercial products include AMZEEQ and ZILXI. The company was founded in October 2011 and is headquartered in Bridgewater, NJ.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
LEPORE PATRICK GDirectorNov 15 '23Buy3.9113,00050,77836,472Nov 17 05:03 PM